Several comorbidities, including diabetes (88.4 vs. 26.4%), coronary artery disease (21.8 vs. 16.5%), chronic kidney disease (17.2 vs. 10.7%), gastroparesis (4.8 vs. 2.2%), heart failure (11.4 vs. 8.7%), and obstructive sleep apnea (25.2 vs. 10.1%) were significantly more prevalent among GLP-1 RA users (all p < 0.01). The gene discussed is GLP1R; the disease is chronic kidney disease.